Economic Evaluation of Dexmedetomidine Relative to Midazolam for Sedation in the Intensive Care Unit

Abstract

Background: Dexmedetomidine is an ␣

Safety and Effectiveness of Dexmedetomidine in the Pediatric Intensive Care Unit (SAD–PICU)

“…A recent Canadian economic comparison of dexmedetomidine and midazolam in critically ill adult patients concluded that although acquisition costs for dexmedetomidine are higher than those for midazolam, the decreased need for mechanical ventilation and delirium management with dexmedetomidine make this drug less costly overall. 29 Given the high frequency of withdrawal symptoms in our study and others, further research into the optimal method of dexmedetomidine discontinuation in critically ill infants and children is also warranted, as well as the long-term, particularly developmental, effects of its use in the pediatric population.…”

Comparison of Dexmedetomidine Versus Propofol on Hospital Costs and Length of Stay

“…4,5 Both evaluations were based on the results of a single randomized study that compared dexmedetomidine to midazolam intravenous (IV) infusions. 6 In this randomized trial known as Safety and Efficacy of Dexmedetomidine Compared With Midazolam (SEDCOM), the median time to start of sedative agent was approximately A subsequent economic evaluation used the data from the SEDCOM trial to perform a cost minimization analysis.…”

Factors that contribute to underrecognition of delirium by registered nurses in acute care settings: a scoping review of the literature to explain this phenomenon

“…). In Canada, there is an increase in healthcare cost of 23·4% (Lachaine & Beauchemin ) for clients diagnosed with delirium. The most important factor affecting the development of delirium is age (Conley ), and more Canadians are expected to experience it as they grow older.…”

“…The longterm consequences of delirium include: greater likelihood of discharge to a place other than home, greater functional decline, increased mortality rate for one year after the incidence of delirium and long-term neuro-cognitive impairment (Vasilevskis et al 2010). In Canada, there is an increase in healthcare cost of 23Á4% (Lachaine & Beauchemin 2012) for clients diagnosed with delirium. The most important factor affecting the development of delirium is age (Conley 2011), and more Canadians are expected to experience it as they grow older.…”